fidexaban has been researched along with Coronary Disease in 1 studies
Fidexaban: structure in first source
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abendschein, DR | 1 |
| Baum, PK | 1 |
| Verhallen, P | 1 |
| Eisenberg, PR | 1 |
| Sullivan, ME | 1 |
| Light, DR | 1 |
1 other study available for fidexaban and Coronary Disease
| Article | Year |
|---|---|
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
Topics: Amidines; Animals; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Blood Coagul | 2001 |